Evonik Evonik

X

Find the latest Drugs in Development and Pipeline Prospector News of SanReno Therapeutics.

Client Virtual Booth
  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
SanReno Therapeutics
China Flag
Country
Country
China
Address
Address
Beijing
Telephone
Telephone
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Novartis will acquire SanReno's pipeline and capabilities, including the exclusive rights for Greater China and Singapore for two late-stage assets targeting IgAN, ABT-627 (atrasentan), an oral ERA antagonist and zigakibart, a subcutaneously administered monoclonal antibody.


Lead Product(s): Atrasentan

Therapeutic Area: Nephrology Product Name: ABT-627

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition January 05, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY